Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPRG | P23470 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875658 | 1.00 | CA2 (0.38) | CA2CA12CA4CA6CA5A | |
| SCHEMBL29586802 | 0.80 | EGFR (0.39) | CA2CA12CA4CA6CA5A | |
| SCHEMBL4500491 | 0.80 | TTR (0.46) | CA2CA12CA4CA6CA5A | |
| SCHEMBL5936407 | 0.80 | EGFR (0.39) | CA2CA12CA4CA6CA5A | |
| SCHEMBL2970964 | 0.80 | EGFR (0.43) | CA2CA12CA4CA6CA5A | |
| SCHEMBL10756643 | 0.80 | KDM4E (0.52) | CA2CA12CA4CA6CA5A | |
| SCHEMBL29987473 | 0.80 | ALOX15 (0.52) | CA2CA12CA4CA6CA5A | |
| SCHEMBL1390986 | 0.80 | ALOX15 (0.52) | CA2CA12CA4CA6CA5A | |
| SCHEMBL14713530 | 0.78 | SLC6A2 (0.43) | CA2CA12CA4CA6CA5A | |
| SCHEMBL307493 | 0.78 | ESR1 (0.40) | CA2CA12CA4CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1931425-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007043542-A9 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2008-05-08 | — | — | WO | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| WO-2007043542-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-19 | — | — | WO | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| US-4185992-A | Imidazole derivatives | MAY & BAKER LIMITED (GB) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA2 3091/4885CA12 4257/4885CA4 1916/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA2 3091/4885CA12 4257/4885CA4 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.